Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00700336 · ClinicalTrials.gov registry record · Phase 1
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
A Phase 1 study, sponsored by CanBas Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT00700336: Completed Phase 1 study, sponsored by CanBas Co..
NCT00700336 is a Phase 1 study that has completed, run by CanBas Co.. The registered enrollment target is 69 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00700336, a Phase 1 study, has completed, sponsored by CanBas Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy. The maximum tolerated dose (MTD) will be determined based on DLTs occurring during the first treatment cycle. Pharmacokinetics of the triplet combination will be assessed during the phase I part of the trial. The phase II part will evaluate full-dose cisplatin and pemetrexed combined with CBP501 (at the MTD determined in the phase I part) in previously untreated, unresectable malignant pleural mesothelioma patients. Patients will be randomized in a 2 : 1 ratio to pemetrexed, cisplatin and CBP501 (Arm A) or to pemetrexed and cisplatin (Arm B); randomization will be stratified according to histology and performance status.
Primary Outcome
Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication.
Interventions
- DRUG pemetrexed, cisplatin and CBP501
- DRUG pemetrexed and cisplatin
- DRUG pemetrexed, cisplatin and CBP501, dose finding
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
What the finished NCT00700336 record still lists
NCT00700336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 3 interventions - of which pemetrexed, cisplatin and CBP501 is the first listed.
NCT00700336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00700336 about?
NCT00700336 is a clinical study titled "Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)". The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or ar...
What is the current status of trial NCT00700336?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2008-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00700336?
The interventions under investigation include: pemetrexed, cisplatin and CBP501 (DRUG), pemetrexed and cisplatin (DRUG), pemetrexed, cisplatin and CBP501, dose finding (DRUG).
Who is sponsoring clinical trial NCT00700336?
This trial is sponsored by CanBas Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00700336's enrollment target sits among peer trials
69 774th of 2000 higher than 1,225 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia